Phase II trial to study treatments for patients with high-grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that may have received at least 2 prior lines of chemotherapy

IRB17-106
Cancer, Cancer-Gynecologic
Tashanna Myers, MD

D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199

This research study is designed to see if olaparib is effective in treating high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer and whether it causes any side effects. A capsule formulation of olaparib (tradename Lynparza™) is approved by both the European Commission (EC), US Food and Drug Administration (FDA) and other countries for the treatment of women with advanced BRCA-mutated ovarian cancer.
Diagnosis of platinum-sensitive epithelial ovarian, fallopian, or primary peritoneal cancer
Laura Sorci
413-794-3188